Reata Announces Receipt of $30 Million Milestone Payment From Kyowa Hakko Kirin
August 30, 2018 18:40 ET
|
Reata Pharmaceuticals, Inc.
IRVING, Texas, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA), a clinical-stage biopharmaceutical company, today announced that it has received a $30 million milestone...
Reata Pharmaceuticals, Inc. Announces Second Quarter 2018 Financial Results and an Update on Development Programs
August 08, 2018 16:01 ET
|
Reata Pharmaceuticals, Inc.
IRVING, Texas, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today provided an update on the Company's product development...
Reata Pharmaceuticals, Inc. to Report Second Quarter 2018 Financial Results and an Update on Development Programs on Wednesday, August 8, 2018
August 06, 2018 17:35 ET
|
Reata Pharmaceuticals, Inc.
IRVING, Texas, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call...
Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
July 27, 2018 11:05 ET
|
Reata Pharmaceuticals, Inc.
IRVING, Texas, July 27, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its...
Reata Pharmaceuticals, Inc. Announces Pricing of Class A Common Stock Public Offering
July 24, 2018 20:52 ET
|
Reata Pharmaceuticals, Inc.
IRVING, Texas, July 24, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering...
Reata Pharmaceuticals, Inc. Announces Proposed Public Offering of Class A Common Stock
July 23, 2018 16:39 ET
|
Reata Pharmaceuticals, Inc.
IRVING, Texas, July 23, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced its intention to...
Reata Announces Positive Phase 2 Data for Bardoxolone Methyl in CKD Caused by Alport Syndrome and Autosomal Dominant Polycystic Kidney Disease
July 23, 2018 06:45 ET
|
Reata Pharmaceuticals, Inc.
Statistically Significant Improvement in Kidney Function Maintained in Alport Syndrome Patients After 48 Weeks of Treatment Statistically Significant Retained Benefit of 4.1 mL/min in Alport Syndrome...
Reata Receives Orphan Drug Designation from the European Commission for Omaveloxolone for the Treatment of Friedreich’s Ataxia
July 10, 2018 16:18 ET
|
Reata Pharmaceuticals, Inc.
IRVING, Texas, July 10, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA), a clinical-stage biopharmaceutical company, today announced that the European Commission has granted...
Reata Announces Initiation of a Phase 1 Trial of RTA 1701, a Selective, Oral Allosteric Inhibitor of RORγt
June 20, 2018 16:18 ET
|
Reata Pharmaceuticals, Inc.
IRVING, Texas, June 20, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA), a clinical-stage biopharmaceutical company, today announced the initiation of a Phase 1 clinical trial of...
Reata Pharmaceuticals, Inc. Secures $125 Million Term Loan Facility
June 14, 2018 16:15 ET
|
Reata Pharmaceuticals, Inc.
IRVING, Texas, June 14, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (“Reata” or “the Company”), a clinical-stage biopharmaceutical company, today announced that it entered...